Department of Psychiatry, The University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-9086, USA.
J Clin Psychiatry. 2011 Jun;72(6):757-64. doi: 10.4088/JCP.11m06837.
Monitoring suicidality and risk following initiation of antidepressant treatment is an essential component of clinical care, but few brief, reliable ratings of suicidal ideation and behavior in adults are available. This report evaluates the psychometric properties of a brief self- and clinician-rated measure of factors related to the risk of suicide attempt or completion.
Adult outpatients with nonpsychotic major depressive disorder (MDD) (n = 240) were enrolled from July 2007 through February 2008 and treated in an 8-week, open-label trial with the clinician's choice of a selective serotonin reuptake inhibitor at 6 primary care and 9 psychiatric clinical care settings in the National Institute of Mental Health-funded Depression Trials Network. Diagnosis of MDD was determined by the Psychiatric Diagnostic Screening Questionnaire and an MDD checklist based on DSM-IV-TR criteria. Suicidal ideation and behavior are 1 of 9 symptoms of MDD (depressed mood, loss of interest, appetite or weight change, sleep disturbance, reduced concentration or indecisiveness, fatigue or decreased energy, psychomotor agitation or retardation, feelings of worthlessness, or excessive guilt). The newly developed Concise Health Risk Tracking (CHRT) scale was administered both as the CHRT Self-Report (CHRT-SR) and Clinician Rating (CHRT-C) scales. Psychometric evaluations were conducted on both scales.
The internal consistency (Cronbach α) was .77 for the 7-item CHRT-C and .78 for the 7-item CHRT-SR with a consistent factor structure, and 3 independent factors (current suicidal thoughts and plans, perceived lack of social support, and hopelessness) for both versions.
The 7-item CHRT-C and the 7-item CHRT-SR have excellent psychometric properties and can be used to monitor suicidal risk in clinical practice and research settings. Whether either scale will predict suicide attempts or completions in actual practice would require a very large prospective study sample.
Clinicaltrials.gov Identifier: NCT00532103.
监测抗抑郁治疗启动后自杀风险是临床护理的重要组成部分,但目前可用的成人自杀意念和行为的简短、可靠评估工具却很少。本报告评估了一种评估与自杀企图或完成风险相关的因素的简短自评和临床医生评定量表的心理测量特性。
2007 年 7 月至 2008 年 2 月期间,来自 6 个初级保健和 9 个精神科临床护理机构的全国精神卫生研究所资助的抑郁症试验网络的非精神病性重度抑郁症(MDD)成年门诊患者(n=240)入组并参加了为期 8 周的开放性试验,使用临床医生选择的选择性 5-羟色胺再摄取抑制剂进行治疗。MDD 的诊断通过精神病诊断筛查问卷和基于 DSM-IV-TR 标准的 MDD 清单确定。自杀意念和行为是 MDD 的 9 种症状之一(抑郁情绪、兴趣丧失、食欲或体重变化、睡眠障碍、注意力或决断力减退、疲劳或精力减退、精神运动激越或迟滞、无价值感或过度内疚感)。新开发的简明健康风险跟踪(CHRT)量表同时作为 CHRT 自评量表(CHRT-SR)和临床医生评定量表(CHRT-C)进行管理。对这两种量表都进行了心理测量评估。
7 项 CHRT-C 的内部一致性(Cronbach α)为.77,7 项 CHRT-SR 的内部一致性为.78,两种版本的结构一致,有 3 个独立的因子(当前自杀意念和计划、感知缺乏社会支持和绝望感)。
7 项 CHRT-C 和 7 项 CHRT-SR 具有极好的心理测量特性,可用于监测临床实践和研究环境中的自杀风险。任何一种量表是否都能在实际实践中预测自杀企图或完成,都需要一个非常大的前瞻性研究样本。
Clinicaltrials.gov 标识符:NCT00532103。